{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:54:58Z","timestamp":1790999698287,"version":"4.1.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,10,1]]},"DOI":"10.2169\/internalmedicine.6894-25","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:09:35Z","timestamp":1771884575000},"page":"2586-2591","source":"Crossref","is-referenced-by-count":1,"title":["\"Et tu, Brute?\" - A Case of Ixazomib - Induced Cancer Therapy-related Cardiac Dysfunction"],"prefix":"10.2169","volume":"65","author":[{"given":"Yusuke","family":"Hirao","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Odagi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Shinkura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Hoshijima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hogara","family":"Nishisaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.","DOI":"10.3322\/caac.21654"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121: 884-892, 2013.","DOI":"10.1182\/blood-2012-05-432203"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119: 4375-4382, 2012.","DOI":"10.1182\/blood-2011-11-395749"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Enrico O, Gabriele B, Nadia C, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138: 396-397, 2007.","DOI":"10.1111\/j.1365-2141.2007.06659.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Grandin EW, Ky B, Cornell RF, Carver J, Lenihan DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 21: 138-144, 2015.","DOI":"10.1016\/j.cardfail.2014.11.008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med 369: 1779-1781, 2013.","DOI":"10.1056\/NEJMp1313140"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol 15: 1503-1512, 2014.","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374: 1621-1634, 2016.","DOI":"10.1056\/NEJMoa1516282"},{"key":"9","doi-asserted-by":"crossref","first-page":"e70038","DOI":"10.1002\/jha2.70038","volume":"6","author":"BJ Lee","year":"2025","unstructured":"9. Lee BJ, Sayer M, Naqvi AA, et al. Balancing the risk of cardiotoxicity outcomes in treatment selection for multiple myeloma: a retrospective multicenter evaluation of ixazomib, lenalidomide, and dexamethasone (IRd) versus carfilzomib, lenalidomide, and dexamethasone (KRd). EJHaem 6: e70038, 2025.","journal-title":"eJHaem","ISSN":"https:\/\/id.crossref.org\/issn\/2688-6146","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366: 818-822, 2019.","DOI":"10.1126\/science.aax3769"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Papanagnou ED, Gumeni S, Sklirou AD, et al. Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity. Aging Cell 21: e13715, 2022.","DOI":"10.1111\/acel.13715"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Navon A, Ciechanover A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 284: 33713-33718, 2009.","DOI":"10.1074\/jbc.R109.018481"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ling Y, Li R, Zhong J, Zhao Y, Chen Z. Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis. Drug Chem Toxicol 45: 1443-1448, 2022.","DOI":"10.1080\/01480545.2020.1835945"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Herrmann J, Wohlert C, Saguner AM, et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 15: 614-623, 2013.","DOI":"10.1093\/eurjhf\/hft034"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hasinoff BB, Patel D, Wu X. Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovasc Toxicol 17: 237-250, 2017.","DOI":"10.1007\/s12012-016-9378-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Mingrone G, Astarita A, Colomba A, et al. Patients with very high risk of cardiovascular adverse events during carfilzomib therapy: prevention and management of events in a single center experience. Cancers (Basel) 15: 1149, 2023.","DOI":"10.3390\/cancers15041149"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dimopoulos MA, Spicka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol 38: 4030-4041, 2020.","DOI":"10.1200\/JCO.20.02060"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70: 1970-1980, 2010.","DOI":"10.1158\/0008-5472.CAN-09-2766"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jouni H, Aubry MC, Lacy MQ, et al. Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors. Am J Hematol 92: 220-221, 2017.","DOI":"10.1002\/ajh.24608"},{"key":"20","unstructured":"20. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43: 4229-4361, 2022."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kitai T, Kohsaka S, Kato T, et al. JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J 89: 1278-1444, 2025.","DOI":"10.1253\/circj.CJ-25-0002"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/19\/65_6894-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:30:46Z","timestamp":1790998246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/19\/65_6894-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":21,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6894-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"6894-25"}}